1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global HIV/AIDS Diagnostics Market
4. Market Overview
    4.1. Introduction
        4.1.1. Definition
        4.1.2. Industry Evolution/Developments
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global HIV/AIDS Diagnostics Market Analysis and Forecast, 2017–2031
        4.4.1. Market Revenue Projection (US$ Mn)
        4.4.2. Market Volume/Unit Shipments Projection
    4.5. Porter’s Five Forces Analysis
5. Key Insights
    5.1. HIV Disease Epidemiology
    5.2. Technological Advancements
    5.3. Key Mergers & Acquisitions
    5.4. COVID-19 Pandemic Impact on Industry (Value Chain and Short/Mid/Long-term Impact)
6. Global HIV/AIDS Diagnostics Market Analysis and Forecast, by Product
    6.1. Introduction & Definition
    6.2. Key Findings/Developments
    6.3. Market Value Forecast, by Product, 2017–2031
        6.3.1. Kits and Reagents
        6.3.2. Instruments
    6.4. Market Attractiveness Analysis, by Product
7. Global HIV/AIDS Diagnostics Market Analysis and Forecast, by Test Type
    7.1. Introduction & Definition
    7.2. Key Findings/Developments
    7.3. Market Value Forecast, by Test Type, 2017–2031
        7.3.1. Nucleic Acid Tests
        7.3.2. Rapid Tests (POC)
        7.3.3. ELISA
        7.3.4. Others
    7.4. Market Attractiveness Analysis, by Test Type
8. Global HIV/AIDS Diagnostics Market Analysis and Forecast, by End-user
    8.1. Introduction & Definition
    8.2. Key Findings/Developments
    8.3. Market Value Forecast, by End-user, 2017–2031
        8.3.1. Hospitals
        8.3.2. Diagnostic Laboratories
        8.3.3. Academic and Research Institutes
        8.3.4. Others
    8.4. Market Attractiveness Analysis, by End-user
9. Global HIV/AIDS Diagnostics Market Analysis and Forecast, by Region
    9.1. Key Findings
    9.2. Market Value Forecast, by Region, 2017–2031
        9.2.1. North America
        9.2.2. Europe
        9.2.3. Asia Pacific
        9.2.4. Latin America
        9.2.5. Middle East & Africa
    9.3. Market Attractiveness Analysis, by Region
10. North America HIV/AIDS Diagnostics Market Analysis and Forecast
    10.1. Introduction
        10.1.1. Key Findings
    10.2. Market Value Forecast, by Product, 2017–2031
        10.2.1. Kits and Reagents
        10.2.2. Instruments
    10.3. Market Value Forecast, by Test Type, 2017–2031
        10.3.1. Nucleic Acid Tests
        10.3.2. Rapid Tests (POC)
        10.3.3. ELISA
        10.3.4. Others
    10.4. Market Value Forecast, by End-user, 2017–2031
        10.4.1. Hospitals
        10.4.2. Diagnostic Laboratories
        10.4.3. Academic and Research Institutes
        10.4.4. Others
    10.5. Market Value Forecast, by Country, 2017–2031
        10.5.1. U.S.
        10.5.2. Canada
    10.6. Market Attractiveness Analysis
        10.6.1. By Product
        10.6.2. By Test Type
        10.6.3. By End-user
        10.6.4. By Country
11. Europe HIV/AIDS Diagnostics Market Analysis and Forecast
    11.1. Introduction
        11.1.1. Key Findings
    11.2. Market Value Forecast, by Product, 2017–2031
        11.2.1. Kits and Reagents
        11.2.2. Instruments
    11.3. Market Value Forecast, by Test Type, 2017–2031
        11.3.1. Nucleic Acid Tests
        11.3.2. Rapid Tests (POC)
        11.3.3. ELISA
        11.3.4. Others
    11.4. Market Value Forecast, by End-user, 2017–2031
        11.4.1. Hospitals
        11.4.2. Diagnostic Laboratories
        11.4.3. Academic and Research Institutes
        11.4.4. Others
    11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
        11.5.1. Germany
        11.5.2. U.K.
        11.5.3. France
        11.5.4. Italy
        11.5.5. Spain
        11.5.6. Rest of Europe
    11.6. Market Attractiveness Analysis
        11.6.1. By Product
        11.6.2. By Test Type
        11.6.3. By End-user
        11.6.4. By Country/Sub-region
12. Asia Pacific HIV/AIDS Diagnostics Market Analysis and Forecast
    12.1. Introduction
        12.1.1. Key Findings
    12.2. Market Value Forecast, by Product, 2017–2031
        12.2.1. Kits and Reagents
        12.2.2. Instruments
    12.3. Market Value Forecast, by Test Type, 2017–2031
        12.3.1. Nucleic Acid Tests
        12.3.2. Rapid Tests (POC)
        12.3.3. ELISA
        12.3.4. Others
    12.4. Market Value Forecast, by End-user, 2017–2031
        12.4.1. Hospitals
        12.4.2. Diagnostic Laboratories
        12.4.3. Academic and Research Institutes
        12.4.4. Others
    12.5. Market Value Forecast, by Country/Sub-region, 2017–2031
        12.5.1. China
        12.5.2. Japan
        12.5.3. India
        12.5.4. Australia & New Zealand
        12.5.5. Rest of Asia Pacific
    12.6. Market Attractiveness Analysis
        12.6.1. By Product
        12.6.2. By Test Type
        12.6.3. By End-user
        12.6.4. By Country/Sub-region
13. Latin America HIV/AIDS Diagnostics Market Analysis and Forecast
    13.1. Introduction
        13.1.1. Key Findings
    13.2. Market Value Forecast, by Product, 2017–2031
        13.2.1. Kits and Reagents
        13.2.2. Instruments
    13.3. Market Value Forecast, by Test Type, 2017–2031
        13.3.1. Nucleic Acid Tests
        13.3.2. Rapid Tests (POC)
        13.3.3. ELISA
        13.3.4. Others
    13.4. Market Value Forecast, by End-user, 2017–2031
        13.4.1. Hospitals
        13.4.2. Diagnostic Laboratories
        13.4.3. Academic and Research Institutes
        13.4.4. Others
    13.5. Market Value Forecast, by Country/Sub-region, 2017–2031
        13.5.1. Brazil
        13.5.2. Mexico
        13.5.3. Rest of Latin America
    13.6. Market Attractiveness Analysis
        13.6.1. By Product
        13.6.2. By Test Type
        13.6.3. By End-user
        13.6.4. By Country/Sub-region
14. Middle East & Africa HIV/AIDS Diagnostics Market Analysis and Forecast
    14.1. Introduction
        14.1.1. Key Findings
    14.2. Market Value Forecast, by Product, 2017–2031
        14.2.1. Kits and Reagents
        14.2.2. Instruments
    14.3. Market Value Forecast, by Test Type, 2017–2031
        14.3.1. Nucleic Acid Tests
        14.3.2. Rapid Tests (POC)
        14.3.3. ELISA
        14.3.4. Others
    14.4. Market Value Forecast, by End-user, 2017–2031
        14.4.1. Hospitals
        14.4.2. Diagnostic Laboratories
        14.4.3. Academic and Research Institutes
        14.4.4. Others
    14.5. Market Value Forecast, by Country/Sub-region, 2017–2031
        14.5.1. GCC Countries
        14.5.2. South Africa
        14.5.3. Rest of Middle East & Africa
    14.6. Market Attractiveness Analysis
        14.6.1. By Product
        14.6.2. By Test Type
        14.6.3. By End-user
        14.6.4. By Country/Sub-region
15. Competition Landscape
    15.1. Market Player – Competition Matrix (by tier and size of companies)
    15.2. Market Share Analysis, by Company (2021)
    15.3. Company Profiles
        15.3.1. Hologic, Inc
            15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.1.2. Product Portfolio
            15.3.1.3. Financial Overview
            15.3.1.4. SWOT Analysis
            15.3.1.5. Strategic Overview
        15.3.2. Abbott
            15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.2.2. Product Portfolio
            15.3.2.3. Financial Overview
            15.3.2.4. SWOT Analysis
            15.3.2.5. Strategic Overview
        15.3.3. Bio-Rad Laboratories, Inc.
            15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.3.2. Product Portfolio
            15.3.3.3. Financial Overview
            15.3.3.4. SWOT Analysis
            15.3.3.5. Strategic Overview
        15.3.4. F. Hoffmann-La Roche Ltd.
            15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.4.2. Product Portfolio
            15.3.4.3. Financial Overview
            15.3.4.4. SWOT Analysis
            15.3.4.5. Strategic Overview
        15.3.5. OraSure Technologies, Inc.
            15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.5.2. Product Portfolio
            15.3.5.3. Financial Overview
            15.3.5.4. SWOT Analysis
        15.3.6. Siemens Healthcare GmbH
            15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.6.2. Product Portfolio
            15.3.6.3. Financial Overview
            15.3.6.4. SWOT Analysis
        15.3.7. Chembio Diagnostics, Inc.
            15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.7.2. Product Portfolio
            15.3.7.3. Financial Overview
            15.3.7.4. SWOT Analysis
        15.3.8. Danaher Corporation
            15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.8.2. Product Portfolio
            15.3.8.3. Financial Overview
            15.3.8.4. SWOT Analysis
        15.3.9. Becton, Dickinson and Company
            15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.9.2. Product Portfolio
            15.3.9.3. Financial Overview
            15.3.9.4. SWOT Analysis
Table 01: Global HIV/AIDS Diagnostics Market Value (US$ Mn) Forecast, by Product, 2017–2031
Table 02: Global HIV/AIDS Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017–2031
Table 03: Global HIV/AIDS Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 04: Global HIV/AIDS Diagnostics Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 05: North America HIV/AIDS Diagnostics Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 06: North America HIV/AIDS Diagnostics Market Value (US$ Mn) Forecast, by Product, 2017–2031
Table 07: North America HIV/AIDS Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017–2031
Table 08: North America HIV/AIDS Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 09: Europe HIV/AIDS Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 10: Europe HIV/AIDS Diagnostics Market Value (US$ Mn) Forecast, by Product, 2017–2031
Table 11: Europe HIV/AIDS Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017–2031
Table 12: Europe HIV/AIDS Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 13: Asia Pacific HIV/AIDS Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 14: Asia Pacific HIV/AIDS Diagnostics Market Value (US$ Mn) Forecast, by Product, 2017–2031
Table 15: Asia Pacific HIV/AIDS Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017–2031
Table 16: Asia Pacific HIV/AIDS Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 17: Latin America HIV/AIDS Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 18: Latin America HIV/AIDS Diagnostics Market Value (US$ Mn) Forecast, by Product, 2017–2031
Table 19: Latin America HIV/AIDS Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017–2031
Table 20: Latin America HIV/AIDS Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 21: Middle East & Africa HIV/AIDS Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 22: Middle East & Africa HIV/AIDS Diagnostics Market Value (US$ Mn) Forecast, by Product, 2017–2031
Table 23: Middle East & Africa HIV/AIDS Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017–2031
Table 24: Middle East & Africa HIV/AIDS Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer



 
			 
					
							
			 
					
							
			 
					
							
			 
					
							
			 
					
							
			 
					
							
			 
					
							
			 
					
							
			